A Comparative Trial of TMS Approaches to Treating Depression
Study Details
Study Description
Brief Summary
Trancranial Magnetic Stimulation (TMS) is a non-drug and non-invasive treatment for depression and has been investigated for the treatment of psychiatric illness for over 15 years. There is now established evidence indicating TMS is an effective treatment for depression. However, the effectiveness of TMS varies between people, thus requiring further research to investigate its optimal application. Investigators want to compare the effectiveness of different forms of TMS, given with differing stimulation settings to the right or left side of the brain that has been associated with depression. This could potentially help clinicians in the future to improve the prescription of TMS as a treatment for depression.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Transcranial Magnetic Stimulation Active TMS (1) |
Device: Transcranial Magnetic Stimulation
|
| Active Comparator: Transcranial Magnetic Stimulation 2 Active TMS (2) |
Device: Transcranial Magnetic Stimulation
|
| Active Comparator: Transcranial Magnetic Stimulation 3 Active TMS (3) |
Device: Transcranial Magnetic Stimulation
|
Outcome Measures
Primary Outcome Measures
- Montgomery-Åsberg Depression Rating Scale(MADRS) [Participants will be assessed for changes for duration of trial, an expected average of 6 weeks.]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years.
-
DSM-IV diagnosis of current Major Depressive Episode.
-
MADRS score of 20 or more.
-
Able to give informed consent.
Exclusion Criteria:
-
DSM-IV psychotic disorder.
-
Drug or alcohol abuse or dependence (preceding 3 months).
-
Inadequate response to ECT (current episode of depression).
-
Rapid clinical response required, e.g. high suicide risk.
-
Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
-
Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.
-
Pregnancy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Black Dog Institute, University of New South Wales | Sydney | New South Wales | Australia | 2052 |
Sponsors and Collaborators
- The University of New South Wales
Investigators
- Principal Investigator: Colleen Loo, MB.BS. (Hons), FRANZCP, MD., Black Dog Institute, University of New South Wales
Study Documents (Full-Text)
None provided.More Information
Publications
- Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. Br J Psychiatry. 2001 Feb;178:145-53. Erratum in: Br J Psychiatry 2001 Dec;179:561-2.
- Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010 Jul;50(7):1153-63. doi: 10.1111/j.1526-4610.2010.01697.x. Epub 2010 Jun 10. Review.
- Kupfer DJ, Frank E. The interaction of drug- and psychotherapy in the long-term treatment of depression. J Affect Disord. 2001 Jan;62(1-2):131-7. Review.
- Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord. 2005 Nov;88(3):255-67. Epub 2005 Sep 2. Review.
- Sachdev PS, McBride R, Loo C, Mitchell PM, Malhi GS, Croker V. Effects of different frequencies of transcranial magnetic stimulation (TMS) on the forced swim test model of depression in rats. Biol Psychiatry. 2002 Mar 15;51(6):474-9.
- Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry. 2009 Jul;43(7):594-605. doi: 10.1080/00048670902970882.
- HC13053